Review
Copyright ©The Author(s) 2022.
World J Gastrointest Endosc. Oct 16, 2022; 14(10): 581-596
Published online Oct 16, 2022. doi: 10.4253/wjge.v14.i10.581
Table 1 Covered versus uncovered self-expandable metal stents in malignant distal biliary obstruction
Ref.
Study design; country
Total number subjects
Number of SEMS Placed, CSEMS vsUSEMS
Recurrent biliary obstruction; CSEMS vsUSEMS, n (%)
Stent patency CSEMS vsUSEMS, d
Procedure related adverse events, CSEMS vsUSEMS, % (n = #)
Sakai et al[13], 2021Multicenter randomized control trial; Japan9244 vs 4810 (22.7%) vs 21 (43.8%), P = 0.0467455 vs 301, P = 0.01126.8% (2 cholangitis, 1 cholecystitis) vs 8.3% (2 pancreatitis, 2 cholangitis), P = 0.549
Conio et al[14], 2018Multicenter randomized control trial; Italy15878 vs 8012 (16.7%) vs 10 (13.2%), P = 0.65240 vs 541, P = 0.03118% (6 cholangitis, 2 cholecystitis, 5 migrations) vs 7.9% (6 cholangitis), P = 0.061
Yang et al[15], 2015Single center randomized control trial; South Korea10351 vs 5217 (33.3%) vs 15 (28.8%), P = 0.623395 vs 365, P = 0.46717.6% (5 cholecystitis, 3 pancreatitis, 1 cholangitis) vs 9.6% (3 cholecystitis, 2 cholangitis), P = 0.378
Lee et al[16], 2013Single center randomized control trial; South Korea4020 vs 2010 (50%) vs 4 (20%), P = 0.047207 vs 413, P = 0.0415% (1 cholecystitis) vs 0%, NS
Lee et al[17], 2014Retrospective, single center; USA749171 vs 57833 (19%) vs 123 (21%), P < 0.001468 vs 799, P = 0.618.2% (10 pancreatitis, 4 cholangitis) vs 6.4% (6 pancreatitis, 3 cholecystitis, 28 cholangitis), P = 0.20
Kitano et al[18], 2013Multicenter randomized control trial; Japan12060 vs 6014 (23%) vs 22 (36%), P = 0.08583 vs 314, P = 0.0193.3% (1 pancreatitis, 1 cholecystitis) vs 3.3% (2 cholecystitis), NS
Telford et al[19], 2010Multicenter randomized control trial; Canada12968 vs 6120 (29%) vs 11 (18%), NS357 vs 711, P = 0.5304.4% (3 cholecystitis) vs 6.6% (3 cholecystitis, 1 pancreatitis), P = 0.046
Kullman et al[20], 2010Multicenter randomized control trial; Sweden379188 vs 19147 (25%) vs 45 (24%), P > 0.50154 vs 199, P = 0.3267.5% (2 cholecystitis,3 pancreatitis, 8 cholangitis, 1 perforation) vs 10.5% (2 cholecystitis,4 pancreatitis, 12 cholangitis, 1 perforation, 1 hemorrhage), P = 0.370
Isayama et al[21], 2004Single center randomized control trial; Japan11257 vs 558 (14%) vs 21 (38.2%), P < 0.001304 vs 161, P < 0.0512.3% (5 pancreatitis, 2 cholecystitis) vs 5.5% (1 pancreatitis, 2 hemorrhage), NS